Register Login

All Posts

Nov 17 2025
george

A Case Study: Congenital Hypofibrinogenemia

Check your medical library for Wu Y, Qin K, Xiang L, et al. Congenital hypofibrinogenemia with bleeding risk: mutations in the FGA, FGB, and FGG genes. Lab Med. 2025:lmaf042. doi: 10.1093/labmed/lmaf042. PMID: 41233956. Abstract Introduction: Congenital hypofibrinogenemia is a genetic disorder caused by defects in the fibrinogen gene. We identified a case of congenital hypofibrinogenemia […]
read more
Comments (0)
Bleeding Disorders
Nov 17 2025
george

FXIa Inhibitor Milvexian Fails Pivotal Test

Because FXI deficiency is associated with mild variable bleeding, researchers have been developing a direct anticoagulant specific to FXIa, intending to provide effective anticoagulation while reducing the bleeding risk that plagues other antithrombotics. Here is a FirstWord Pharma post in which Bristol-Myers Squibb and Johnson & Johnson report an interim finding in their Librexia ACS (acute […]
read more
Comments (0)
Anticoagulant Therapy
Nov 14 2025
george

Commentary: Laboratory Implications of Transitioning from DOACs to Heparin.

Click here for an 11-13-2025  open-access article, Arachchillage DJ, Vinayagam S, Parsons A, Karawitage N, Laffan M. Transitioning of patients from direct-acting oral anticoagulant to heparin: impact on laboratory testing. Semin Thromb Hemost. 2025. doi: 10.1055/a-2734-2293. PMID: 41232561. Abstract Direct oral anticoagulants (DOACs), including direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors (apixaban, rivaroxaban, […]
read more
Comments (0)
Anticoagulant Therapy
Nov 14 2025
george

Coag Conversation About Alternative Methods to Monitor Anticoagulant Therapy Part 2: Anticoagulation for Antiphospholipid Syndrome

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click Anticoagulation […]
read more
Comments (0)
Anticoagulant Therapy
Nov 12 2025
george

Alternate Functions of AT, PC, PS, and TFPI

Go to your medical library to download the meta-analysis Prouse T, Mast AE, Ignjatovic V, Kovac M, Bereczky Z, Majumder R. Alternate functions of physiological anticoagulants. J Thromb Haemost. 2025:S1538-7836(25)00540-9. doi: 10.1016/j.jtha.2025.08.014. PMID: 40907701. Abstract The anticoagulant proteins antithrombin, protein C, protein S, and tissue factor pathway inhibitor are physiological regulators of the blood coagulation […]
read more
Comments (0)
Thrombophilia
Oct 31 2025
george

Analysis of Antiphospholipid Antibody Testing

Select an open-access article, Thirunavukarasu C, PasalicL, Favaloro EJ. A contemporary analysis of solid-phase antiphospholipid antibody testing: implications for classification or diagnosis of antiphospholipid syndrome, Pathology, https://doi.org/10.1016/j.pathol.2025.07.003   for a look at current ACL and anti β-2 glycoprotein 1 assays and their efficacy in diagnosing APS. Abstract Antiphospholipid antibody (aPL) testing is required for diagnosis of […]
read more
Comments (0)
Thrombophilia
Load more

George Fritsma MS MLS

George Fritsma is a medical laboratory scientist, educator, and author. George  is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

Cheat Sheets from George

Name

Questions or Comments?

Email George

Quick Question

What VWD subtype Is caused by a VWF gain of function?